M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 21, 2010
April 24, 2020
fab84a39-1f07-487f-ae13-2eb2b1884d18
Related Documents
Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry
Guidance DocumentApril 12, 2011Center for Drug Evaluation and Research
M3(R2)Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals: Questions and Answers
Guidance DocumentMarch 13, 2013Center for Drug Evaluation and Research
S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals
Guidance DocumentSeptember 17, 2008Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox